Trial · NCT01717313
Results by group32
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 32
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Hemoglobin A1c (A1C) at Week 24 (Phase A, FAS Population) | Omarigliptin | -0.49 | 95% Confidence Interval -0.73 to -0.24 | Percent | |
| Change From Baseline in Hemoglobin A1c (A1C) at Week 24 (Phase A, FAS Population) | Placebo to Omarigliptin | -0.10 | 95% Confidence Interval -0.34 to 0.14 | Percent | |
| Percentage of Participants Who Experienced at Least One Adverse Event in Phase A (Excluding Data After Glycemic Rescue, Safety Population) | Omarigliptin | 41.8 | Percentage of participants | ||
| Percentage of Participants Who Experienced at Least One Adverse Event in Phase A (Excluding Data After Glycemic Rescue, Safety Population) | Placebo to Omarigliptin | 50.0 | Percentage of participants | ||
| Percentage of Participants Who Discontinued From the Study Drug Due to an Adverse Event in Phase A (Excluding Data After Glycemic Rescue, Safety Population) | Omarigliptin | 2.4 | Percentage of participants | ||
| Percentage of Participants Who Discontinued From the Study Drug Due to an Adverse Event in Phase A (Excluding Data After Glycemic Rescue, Safety Population) | Placebo to Omarigliptin | 1.8 | Percentage of participants | ||
| Percentage of Participants Who Experienced at Least One Adverse Event (Phase A + Phase B, Excluding Data After Glycemic Rescue, Safety Population) | Omarigliptin | 54.5 | Percentage of participants | ||
| Percentage of Participants Who Experienced at Least One Adverse Event (Phase A + Phase B, Excluding Data After Glycemic Rescue, Safety Population) | Placebo to Omarigliptin | 60.4 | Percentage of participants | ||
| Percentage of Participants Who Discontinued From the Study Drug Due to an Adverse Event (Phase A + Phase B, Excluding Data After Glycemic Rescue, Safety Population) | Omarigliptin | 3.0 | Percentage of participants | ||
| Percentage of Participants Who Discontinued From the Study Drug Due to an Adverse Event (Phase A + Phase B, Excluding Data After Glycemic Rescue, Safety Population) | Placebo to Omarigliptin | 2.4 | Percentage of participants | ||
| Percentage of Participants Who Achieve an A1C Goal of <7% (53 mmol/Mol) at Week 24 (Phase A, FAS Population) | Omarigliptin | 36.5 | 95% Confidence Interval 29.3 to 44.5 | Percentage of participants | |
| Percentage of Participants Who Achieve an A1C Goal of <7% (53 mmol/Mol) at Week 24 (Phase A, FAS Population) | Placebo to Omarigliptin | 16.3 | 95% Confidence Interval 11.3 to 22.9 | Percentage of participants | |
| Percentage of Participants Who Achieve an A1C Goal of <6.5% (48 mmol/Mol) at Week 24 (Phase A, FAS Population) | Omarigliptin | 16.4 | 95% Confidence Interval 11.4 to 23.1 | Percentage of participants | |
| Percentage of Participants Who Achieve an A1C Goal of <6.5% (48 mmol/Mol) at Week 24 (Phase A, FAS Population) | Placebo to Omarigliptin | 5.0 | 95% Confidence Interval 2.5 to 9.6 | Percentage of participants | |
| Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 (Phase A, FAS Population) | Omarigliptin | -12.8 | 95% Confidence Interval -25.2 to -0.3 | mg/dL | |
| Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 (Phase A, FAS Population) | Placebo to Omarigliptin | -2.5 | 95% Confidence Interval -15.0 to 10.1 | mg/dL | |
| Change From Baseline in 2-hour Post Meal Glucose (PMG) at Week 24 (Phase A, FAS Population) | Omarigliptin | -25.6 | 95% Confidence Interval -56.0 to 4.8 | mg/dL | |
| Change From Baseline in 2-hour Post Meal Glucose (PMG) at Week 24 (Phase A, FAS Population) | Placebo to Omarigliptin | -13.9 | 95% Confidence Interval -43.5 to 15.6 | mg/dL | |
| Change From Baseline in A1C at Week 54 (Phase A + Phase B, FAS Population) | Omarigliptin | -0.40 | 95% Confidence Interval -0.67 to -0.13 | Percent | |
| Change From Baseline in A1C at Week 54 (Phase A + Phase B, FAS Population) | Placebo to Omarigliptin | -0.80 | 95% Confidence Interval -1.07 to -0.53 | Percent |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01717313/results